Is Ibogaine Safe? Side Effects, Heart Risks and Medical Screening

Ibogaine can be given with a much lower risk when patients are carefully screened and their heart is monitored continuously, but it is never risk-free. Its most serious side effect is a temporary lengthening of the heart's QT interval, which can cause dangerous arrhythmias. Most reported deaths involved undiagnosed heart disease, drug interactions, or treatment without medical supervision. This guide explains the common and serious side effects, who should not take ibogaine, and what a safe medical protocol looks like.

Key takeaways

• Common, expected effects: nausea and vomiting, loss of coordination (ataxia), tremor, light sensitivity, insomnia and fatigue for a few days.
• Serious risks: QT prolongation, slow heart rate, ventricular arrhythmias (torsades de pointes), seizures during alcohol or benzodiazepine withdrawal, and psychiatric reactions in vulnerable people.
• A 2012 forensic review found 19 deaths linked to ibogaine between 1990 and 2008, most with identifiable risk factors.
• In controlled medical settings with screening and monitoring, serious cardiac events have been rare.
• Safety depends on four things: screening, electrolyte correction, continuous EKG monitoring and on-site emergency capability.

Common side effects of ibogaine

Most patients experience several of these during the first 24 to 72 hours. They are expected and are managed by the medical team:

• Nausea and vomiting, especially in the first hours of the session.
• Ataxia: difficulty coordinating movement. Patients stay in bed and need help to walk.
• Tremor and muscle weakness.
• Visual changes: sensitivity to light, trails or dream-like images, mostly with eyes closed.
• Sensitivity to sound.
• Insomnia for one to three nights after the session.
• Fatigue and low mood during recovery, sometimes called the "gray day."
• Dry mouth and headache, usually mild.

Serious risks

QT prolongation and arrhythmia

The QT interval is the time the heart's ventricles take to recharge between beats. Ibogaine and its metabolite noribogaine block hERG potassium channels, which slows this recharging and lengthens the QT interval on an EKG. The effect can last beyond the acute session because noribogaine stays in the body for days. If the QT becomes too long, especially when potassium or magnesium are low, it can trigger torsades de pointes, a ventricular arrhythmia that can be fatal. Ibogaine can also slow the heart rate and change blood pressure.

Seizures

Ibogaine itself rarely causes seizures, but withdrawal from alcohol or benzodiazepines can. Combining the two is dangerous. People dependent on these substances must complete a medical detox and be stable before ibogaine is considered.

Drug interactions

Many medications either lengthen the QT interval themselves (some antidepressants, antipsychotics, antibiotics, antifungals, methadone) or block CYP2D6, the liver enzyme that processes ibogaine (for example fluoxetine, paroxetine and bupropion), which can raise ibogaine levels. Stimulants such as cocaine and methamphetamine add cardiac stress. Every medication and supplement must be reviewed and, when needed, tapered safely before treatment.

Psychiatric reactions

People with a personal or family history of psychosis, schizophrenia or bipolar disorder may experience mania or psychotic symptoms. These are exclusion criteria in responsible programs.

What the research says about deaths

A 2012 review in the Journal of Forensic Sciences by Alper and colleagues analyzed 19 deaths that occurred within 76 hours of ibogaine ingestion between 1990 and 2008. In most cases where a post-mortem was available, the person had pre-existing heart disease, or had used other drugs such as opioids or cocaine around the time of treatment. Many of these deaths happened in settings without medical supervision. TIME's 2021 investigation reached the same conclusion: some facilities monitor heart activity throughout treatment while others do not, and that difference matters.

At the same time, published research in controlled settings is encouraging. The 2024 Stanford study in Nature Medicine treated 30 veterans with ibogaine plus intravenous magnesium, which helps protect the heart, and reported no serious adverse events. A 2018 case series of 191 patients treated with medical monitoring, published in Frontiers in Pharmacology, reported no significant toxicity at doses that blocked opioid withdrawal. These are small studies, so the honest summary is: risk can be reduced a great deal, but not eliminated.

Who should not take ibogaine

Common exclusion criteria include:

• Structural heart disease, heart failure, prior heart attack or significant arrhythmia.
• A baseline QTc that is already prolonged, or a personal or family history of long QT syndrome, fainting of unknown cause or sudden cardiac death.
• Significant liver disease, which affects how ibogaine is processed.
• Psychosis, schizophrenia or bipolar disorder.
• Pregnancy or breastfeeding.
• Medications that cannot be safely stopped.
• Active dependence on alcohol or benzodiazepines without prior medical detox.

What safe medical screening includes

Before a patient is accepted, a responsible clinic reviews:

1. Full medical and psychiatric history, including every medication and supplement.
2. 12-lead EKG to measure the baseline QTc interval and rhythm.
3. Echocardiogram and, when indicated, a stress test or Holter monitor, reviewed by a cardiologist.
4. Blood tests: complete blood count, electrolytes (potassium, magnesium, calcium), kidney and liver function, and hepatitis screening.
5. A substance-specific plan: for example, transitioning from long-acting opioids like methadone or fentanyl to short-acting ones for a period before treatment.

How we monitor the heart during treatment

At Ibogaine Center Cancún, our protocol is built around the risks described above:

• On-site cardiologist, 24/7: a cardiologist is physically present in the facility throughout the active phase, not on call from elsewhere.
• Continuous multi-lead EKG telemetry: heart rhythm and QTc are tracked in real time from the test dose until the effect has subsided.
• Electrolyte optimization: potassium and magnesium are checked and corrected intravenously before and during treatment.
• 1-on-1 ACLS nursing: each patient has a dedicated nurse certified in Advanced Cardiac Life Support.
• Emergency readiness: defibrillator, crash cart and emergency medications on site, and a transfer plan to a hospital in Cancún.
• Only 6 private suites, so medical attention is never divided across a large group.

Frequently asked questions

Is ibogaine safe for the heart?

Ibogaine affects the heart in every patient by lengthening the QT interval. In people without heart disease, with normal electrolytes, no interacting drugs and continuous monitoring, the risk of a serious event is low, but it is not zero. That is why cardiac screening and bedside monitoring are non-negotiable.

How long do ibogaine side effects last?

Nausea, ataxia and visual effects usually fade within 24 to 36 hours. Fatigue, insomnia and light sensitivity can continue for two to five days. Because noribogaine remains in the body, heart monitoring continues for at least 24 to 72 hours after the dose.

Can you die from ibogaine?

Yes, deaths have been reported, mostly in people with heart conditions, those who used other drugs during treatment, or those treated without medical supervision. Careful screening and continuous cardiac monitoring are the most important ways to reduce this risk.

Why is magnesium given with ibogaine?

Low magnesium and potassium make QT-related arrhythmias more likely. Correcting them before and during treatment helps stabilize the heart's electrical activity. The 2024 Stanford study gave intravenous magnesium alongside ibogaine for this reason.

References

• Alper, K. R., Stajić, M. and Gill, J. R. "Fatalities temporally associated with the ingestion of ibogaine." Journal of Forensic Sciences, 2012.
• Koenig, X. and Hilber, K. "The anti-addiction drug ibogaine and the heart: a delicate relation." Molecules, 2015.
• Mash, D. C. et al. "Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes." Frontiers in Pharmacology, 2018.
• Cherian, K. N. et al. "Magnesium–ibogaine therapy in veterans with traumatic brain injuries." Nature Medicine, 2024.
• Oaklander, M. "Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction." TIME, 2021.

Your safety starts before you arrive. Our cardiologist reviews your EKG, labs and medications as part of a confidential screening. Start your medical screening.